Showing 2191-2200 of 2652 results for "".
- Seoul Semiconductor Proves the Effect of SunLike Lighting on Myopia Improvementhttps://modernod.com/news/seoul-semiconductor-proves-the-effect-of-sunlike-lighting-on-myopia-improvement/2480573/Seoul Semiconductor announced that it has confirmed SunLike lighting’s effect on improving myopia, along with SERI_Singapore Eye Research Institute. In order to prove the correlation between health and SunLike, a natural lighting technology developed through years of R&D,
- Glaukos Announces FDA 510(k) Clearance of iPRIME Viscodelivery Systemhttps://modernod.com/news/glaukos-announces-fda-510k-clearance-of-iprime-viscodelivery-system/2480553/Glaukos announced that it has received 510(k) clearance from the FDA for the iPRIME Viscodelivery System, a sterile, single-use, minimally-invasive device for the delivery of viscoelastic fluid during ophthalmic surgery. “Since the introduction of our first&nb
- Glaukos Announces Retirement of William J. Link, PhD, as Chairman of the Board; and Election of Thomas W. Burns as New Chairmanhttps://modernod.com/news/glaukos-announces-retirement-of-william-j-link-phd-as-chairman-of-the-board-and-election-of-thomas-w-burns-as-new-chairman/2480530/Glaukos announced that William J. Link, PhD, will be retiring as Chairman of the Board, effective December 31, 2021. Dr. Link joined Glaukos’ Board and has served as Chairman since June 2001. In connection with Dr. Link’s retirement, the Board has appointed Thomas W. Burns, Glaukos&rs
- CORE Names “Top 10 of 2021” Scientific Papers for Eye Care Communityhttps://modernod.com/news/core-names-top-10-of-2021-scientific-papers-for-eye-care-community/2480525/In a year like no other, the Centre for Ocular Research & Education (CORE) has published a record 66 scientific and clinical educational papers on topics that advance academic and clinical knowledge in optometry and ophthalmology. The organization today announced its “Top 10 o
- Foundation Fighting Blindness and Nixon Visions Foundation Collaborate to Combat Inherited Retinal Diseaseshttps://modernod.com/news/foundation-fighting-blindness-and-nixon-visions-foundation-collaborate-to-combat-inherited-retinal-diseases/2480523/The Foundation Fighting Blindness announced the launch of the Nixon Visions Foundation Inherited Macular Dystrophy Program formed through a collaboration with the Nixon Visions Foundation. The program will provide funding for six early translational research projects over 3 years for the dev
- New Technology, Greater Patient Awareness Will Help Drive Gains in Premium Cataract Surgeryhttps://modernod.com/news/new-technology-greater-patient-awareness-will-help-drive-gains-in-premium-cataract-surgery/2480489/Gains in the premium cataract surgery market over the next 5 years will be driven by technological improvements, growing value awareness among patients, declining reimbursement in the public
- Alimera Sciences Welcomes Ophthalmic Strategic Consultant Erin Parsons to Its Board of Directorshttps://modernod.com/news/alimera-sciences-welcomes-ophthalmic-strategic-consultant-erin-parsons-to-its-board-of-directors/2480483/Alimera Sciences announced the addition of Erin Parsons to its Board of Directors. Ms. Parsons has more than 20 years of experience working in the ophthalmic industry overseeing scientific strategy, medical communications, advocacy development, and peer-to-peer educational programs, muc
- CooperVision Launches Student Myopia Leadership Societyhttps://modernod.com/news/coopervision-launches-student-myopia-leadership-society/2480444/CooperVision has launched the CooperVision Student Myopia Leadership Society. Each of the 23 schools and colleges of optometry across the United States and Canada have designated a third-year student for participation, based on their interest in the disease, academic performance and other school-
- iSTAR Medical Present Final Results From STAR-II European Trial for MINIject in Glaucoma Patients at AAOhttps://modernod.com/news/istar-medical-present-final-results-from-star-ii-european-trial-for-miniject-in-glaucoma-patients-at-aao/2480433/iSTAR Medical announced final results of the STAR-II European trial for its MIGS device, MINIject. These data show consistently outstanding performance and a favorable safety profile in patients with primary open-angle glaucoma up to 2 years of follow-up. The trial results will be presented at th
- Unity Biotechnology Announces Improvement in Visual Acuity Sustained Through 24 Weeks in Phase 1 Study of Patients with Advanced Vascular Eye Diseasehttps://modernod.com/news/unity-biotechnology-announces-improvement-in-visual-acuity-sustained-through-24-weeks-in-phase-1-study-of-patients-with-advanced-vascular-eye-disease/2480419/Unity Biotechnology announced 24-week data from its phase 1 single ascending dose (SAD) safety study of UBX1325 in patients wit